Jose L. Lopez-Ribot to Fluconazole
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Fluconazole.
Connection Strength
2.911
-
Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2014; 58(2):1183-6.
Score: 0.480
-
Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
Score: 0.402
-
Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003 Feb; 41(2):619-22.
Score: 0.227
-
Ramage G, VandeWalle K, Bachmann SP, Wickes BL, L?pez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002 Nov; 46(11):3634-6.
Score: 0.223
-
Ramage G, Bachmann S, Patterson TF, Wickes BL, L?pez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother. 2002 Jun; 49(6):973-80.
Score: 0.217
-
Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
Score: 0.206
-
Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, La Valle R, Patterson TF. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Clin Diagn Lab Immunol. 1999 Sep; 6(5):665-70.
Score: 0.179
-
Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov; 42(11):2932-7.
Score: 0.169
-
Vila T, Lopez-Ribot JL. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother. 2017 01; 61(1).
Score: 0.149
-
Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
Score: 0.137
-
Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, L?pez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003 Nov; 47(11):3657-9.
Score: 0.060
-
Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
Score: 0.055
-
Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
Score: 0.054
-
Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
Score: 0.054
-
Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.
Score: 0.053
-
Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul; 43(7):1621-30.
Score: 0.044
-
Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011 Sep; 7(9):e1002257.
Score: 0.026
-
Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
Score: 0.025
-
Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. PLoS One. 2011 Apr 22; 6(4):e19036.
Score: 0.025
-
Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
Score: 0.018
-
S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol. 2005 Aug; 43(8):4159-62.
Score: 0.017
-
Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
Score: 0.016
-
Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
Score: 0.014
-
Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
Score: 0.013
-
Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
Score: 0.013
-
Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
Score: 0.013
-
Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 1999 Dec; 37(12):3896-900.
Score: 0.011
-
Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
Score: 0.011